3G-detection trial
- Conditions
- gastric cancer,esophageal cancer
- Registration Number
- JPRN-jRCT1032210213
- Lead Sponsor
- Yano Tomonori
- Brief Summary
Efficacy analysis (primary endpoint) detection rate of gastric epithelial tumor lesions in non-magnification observation at initial observation (comparison of 3 groups) was Group B (NBI) 7.3% > Group C (TXI) 5.0%, and B Group (NBI) exceeded the control group A (WLI) by 5.6% by more than 1.0%. Based on this, group B (NBI) is a more promising observation method and was judged to be appropriate as the observation group for the next confirmatory study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 901
1)Aged 20 to 85 years old at the time of obtaining consent.
2)Fulfill any of the following [1]-[3].
[1]Have a history of endoscopic treatment for early gastric cancer and/or gastric adenoma, and endoscopic examination is scheduled on the purpose of follow-up.
[2]Have a history of endoscopic treatment, chemotherapy, or radiotherapy for esophageal cancer, and endoscopic examination is scheduled on the purpose of follow-up.
[3]Has a lesion diagnosed as gastric cancer, gastric adenoma, or esophageal cancer, and endoscopic examination is scheduled on the purpose of detailed examination.
3)Written informed consent has been obtained for participation in the study.
1)Have a history of gastrectomy.
2)Have a history of gastric tube reconstruction after esophagectomy.
3)Judged as inappropriate for carrying out this study, including the underlying disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method